These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 35061022)

  • 1. Real-world Evidence of Efficacy and Safety of SGLT2 Inhibitors as Adjunctive Therapy in Adults With Type 1 Diabetes: A European Two-Center Experience.
    Palanca A; van Nes F; Pardo F; Ampudia Blasco FJ; Mathieu C
    Diabetes Care; 2022 Mar; 45(3):650-658. PubMed ID: 35061022
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Assessing the risk of ketoacidosis due to sodium-glucose cotransporter (SGLT)-2 inhibitors in patients with type 1 diabetes: A meta-analysis and meta-regression.
    Musso G; Sircana A; Saba F; Cassader M; Gambino R
    PLoS Med; 2020 Dec; 17(12):e1003461. PubMed ID: 33373368
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical and Safety Outcomes With GLP-1 Receptor Agonists and SGLT2 Inhibitors in Type 1 Diabetes: A Real-World Study.
    Edwards K; Li X; Lingvay I
    J Clin Endocrinol Metab; 2023 Mar; 108(4):920-930. PubMed ID: 36268825
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sodium-glucose cotransporter 2 inhibitors as an add-on therapy to insulin for type 1 diabetes mellitus: Meta-analysis of randomized controlled trials.
    Rao L; Ren C; Luo S; Huang C; Li X
    Acta Diabetol; 2021 Jul; 58(7):869-880. PubMed ID: 33651228
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Do the benefits of sodium-glucose cotransporter 2 inhibitors exceed the risks in patients with type 1 diabetes?
    Kamoshima H; Nomoto H; Yamashita K; Takahashi Y; Tsuchida K; Kuwabara S; Miya A; Cho KY; Kameda H; Nakamura A; Atsumi T; Taneda S; Kurihara Y; Aoki S; Ono Y; Miyoshi H
    Endocr J; 2022 May; 69(5):495-509. PubMed ID: 34819409
    [TBL] [Abstract][Full Text] [Related]  

  • 6. SGLT2 Inhibitors: A Systematic Review of Diabetic Ketoacidosis and Related Risk Factors in the Primary Literature.
    Burke KR; Schumacher CA; Harpe SE
    Pharmacotherapy; 2017 Feb; 37(2):187-194. PubMed ID: 27931088
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety of sodium-glucose cotransporter 2 inhibitors (SGLT2i) during the month of Ramadan in patients with type 2 diabetes mellitus in Pakistani population-an observational study from a tertiary care center in Karachi.
    Sheikh A; Das B; Sattar S; Islam N
    Endocrine; 2023 Apr; 80(1):64-70. PubMed ID: 36580199
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Diabetic euglycemic ketosis or ketoacidosis in individuals with type 2 diabetes treated by SGLT2 inhibitors: A series of Belgian clinical cases].
    Menghoum N; Oriot P; Hermans MP; Mariage JL
    Rev Med Interne; 2020 Apr; 41(4):226-231. PubMed ID: 31866073
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Real-world evaluation of insulin requirements after GLP1 agonist or SGLT2 inhibitor initiation and titration.
    George J; Lobkovich A; Nardolillo J; Farhat N; Kolander S; Thomas E
    Am J Health Syst Pharm; 2022 Jul; 79(14):1151-1157. PubMed ID: 35136945
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety and efficacy of sodium glucose co-transporter 2 inhibitors combined with insulin in adults with type 1 diabetes: A meta-analysis of randomized controlled trials.
    Li K; Xu G
    J Diabetes; 2019 Aug; 11(8):645-655. PubMed ID: 30565398
    [TBL] [Abstract][Full Text] [Related]  

  • 11. On-label use of sodium-glucose cotransporter 2 inhibitors might increase the risk of diabetic ketoacidosis in patients with type 1 diabetes.
    Horii T; Oikawa Y; Atsuda K; Shimada A
    J Diabetes Investig; 2021 Sep; 12(9):1586-1593. PubMed ID: 33448127
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sodium Glucose Cotransporter-2 Inhibitor Treatment and the Risk of Diabetic Ketoacidosis in Denmark: A Retrospective Cohort Study of Five Years of Use.
    Laursen HVB; Røikjer JB; Dal J; Jensen MH
    Curr Drug Saf; 2021; 16(1):73-81. PubMed ID: 32814538
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [SGLT 2 inhibitors in Type 1 diabetes].
    Stougaard EB; Amadid H; Søndergaard E; Jørgensen ME; Persson F; Rossing P
    Ugeskr Laeger; 2020 Aug; 182(35):. PubMed ID: 32829747
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Demographic and clinical characteristics of patients with type 1 diabetes mellitus initiating sodium-glucose cotransporter 2 inhibitors in Japan: A real-world administrative database analysis.
    Abiru N; Shoji S; Kosakai Y; Snijder R; Asakawa K; Rokuda M
    Diabetes Res Clin Pract; 2022 Aug; 190():109973. PubMed ID: 35760156
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Diabetic ketoacidosis in patients treated with SGLT2 inhibitors: experience at a tertiary hospital.
    Papanastasiou L; Glycofridi S; Gravvanis C; Skarakis N; Papadimitriou I; Kanti G; Kapsali C; Kounadi T
    Hormones (Athens); 2021 Jun; 20(2):369-376. PubMed ID: 33151508
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Real life evaluation of sodium-glucose cotransporter 2 inhibition in type 1 diabetes and the risk of diabetic ketoacidosis.
    Stougaard EB; Kristensen PL; Kielgast U; Andersen HU; Hamid Y; Gæde PH; Søndergaard E; Dørflinger GH; Fjeldborg KK; Hansen KW; Thomsen HH; Al-Imar TMJ; Røder M; Sridhar VS; Cherney D; Rossing P; Persson F
    Diab Vasc Dis Res; 2022; 19(5):14791641221130043. PubMed ID: 36262089
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Barriers to initiating SGLT2 inhibitors in diabetic kidney disease: a real-world study.
    Jeong SJ; Lee SE; Shin DH; Park IB; Lee HS; Kim KA
    BMC Nephrol; 2021 May; 22(1):177. PubMed ID: 33990175
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Potential role of SGLT2 inhibitors in the management of type 1 diabetes].
    Philips JC; Paquot N; Scheen AJ
    Rev Med Suisse; 2019 Aug; 15(659):1426-1430. PubMed ID: 31436057
    [TBL] [Abstract][Full Text] [Related]  

  • 19. SGLT2 Inhibitor-associated Diabetic Ketoacidosis: Clinical Review and Recommendations for Prevention and Diagnosis.
    Goldenberg RM; Berard LD; Cheng AYY; Gilbert JD; Verma S; Woo VC; Yale JF
    Clin Ther; 2016 Dec; 38(12):2654-2664.e1. PubMed ID: 28003053
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and safety of combination therapy with SGLT2 and DPP4 inhibitors in the treatment of type 2 diabetes: A systematic review and meta-analysis.
    Cho YK; Kang YM; Lee SE; Lee J; Park JY; Lee WJ; Kim YJ; Jung CH
    Diabetes Metab; 2018 Nov; 44(5):393-401. PubMed ID: 29449146
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.